Drug intelligence / Profile preview

BRZ-105

Development stage: Preclinical
Lead developer: Breeze Bio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems

Overview

BRZ-105 is an mRNA-based therapeutic candidate being developed by BreezeBio (formerly GenEdit) for the treatment of various autoimmune diseases. Utilizing the company's proprietary NanoGalaxy® platform, the drug consists of mRNA encoding multiple autoantigens encapsulated within Hybrid Nanoparticles (HNPs). The mechanism of action involves the targeted delivery of these mRNA sequences to antigen-presenting cells (APCs) to induce antigen-specific immune tolerance, potentially by co-delivering tolerogenic factors. This approach aims to selectively reprogram the immune system to cease its attack on self-tissues without causing broad, systemic immunosuppression. As of early 2024, BRZ-105 is in the lead optimization stage of preclinical development.

Beyond the preview

Go deeper on BRZ-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRZ-105.

Explore the full profile